Core Viewpoint - Dyne Therapeutics, Inc. has announced an upsized underwritten public offering of 18,980,478 shares at a price of $18.44 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of 18,980,478 shares of common stock priced at $18.44 each, with expected gross proceeds of $350 million [1]. - The offering is set to close on or about December 11, 2025, pending customary closing conditions [1]. - Dyne has granted underwriters a 30-day option to purchase an additional 2,847,071 shares at the public offering price [1]. Group 2: Underwriters - Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering [2]. Group 3: Regulatory Information - The offering is made under a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Group 4: Company Overview - Dyne Therapeutics focuses on improving the functionality of individuals with genetically driven neuromuscular diseases, developing therapeutics targeting muscle and the central nervous system [5]. - The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), along with preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5].

Core Viewpoint - Top Wealth Group Holding Limited has announced a public offering of 720,000 units at a price of $7.00 per unit, aiming to raise approximately $5.04 million before expenses [1][3]. Group 1: Offering Details - The offering consists of one Class A ordinary share and two types of warrants (Series A and Series B) [1]. - The Class A Warrants have an exercise price of $7.00 and are immediately exercisable, with Series A Warrants expiring in five years and Series B Warrants in eighteen months [1]. - The closing of the offering is expected around December 10, 2025, pending customary closing conditions [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are estimated at approximately $5.04 million, excluding placement agent fees and other expenses [3]. - If fully exercised, the Class A Warrants could generate an additional gross proceeds of about $10.08 million [3]. - The net proceeds will be used for general corporate and working capital purposes [3]. Group 3: Company Overview - Top Wealth Group Holding Limited is incorporated in the Cayman Islands and operates through its subsidiary in Hong Kong [6]. - The company specializes in premium-class sturgeon caviar and has a brand named "Imperial Cristal Caviar," which has seen significant sales growth since its launch [6]. - The caviar products are endorsed with CITES permits, allowing for legal international trade [6].

Core Viewpoint - Reed's, Inc. has successfully closed a public offering of 2,500,000 shares of common stock and warrants, aiming to enhance liquidity and visibility for shareholders while pursuing long-term profitability [1][3]. Group 1: Offering Details - The public offering included 2,500,000 shares of common stock and warrants, sold at a combined price of $4.00 per share [1]. - The warrants have an exercise price of $4.50 per share, are immediately exercisable, and will expire in five years [1]. - Gross proceeds from the offering are approximately $10 million, before deducting underwriting discounts and commissions [3]. Group 2: Stock Exchange Listing - Reed's common stock was approved for listing on the NYSE American and began trading on December 5, 2025, terminating its previous trading on the OTCQX Best Market [2]. Group 3: Management Commentary - The CEO of Reed's emphasized that the move to NYSE American reflects the company's commitment to growth and delivering value to shareholders [3]. Group 4: Company Background - Reed's, established in 1989, is a leader in craft beverages, offering high-quality, premium, better-for-you beverages under the Reed's®, Virgil's®, and Flying Cauldron® brand names, with products sold in over 32,000 stores nationwide [6]. Group 5: Underwriters - A.G.P./Alliance Global Partners acted as the sole book-running manager for the offering, with Roberts & Ryan, Inc. serving as a co-manager [4].

Core Viewpoint - Reed's, Inc. has announced a public offering of 2,500,000 shares of common stock and warrants, aiming to raise approximately $10 million before expenses, with the offering expected to close on December 8, 2025 [2][3]. Group 1: Offering Details - The public offering price for the combined shares and warrants is set at $4.00, with warrants having an exercise price of $4.50 and an expiration of five years from the issuance date [1]. - Reed's has granted underwriters a 45-day option to purchase an additional 375,000 shares and/or warrants at the public offering prices [1]. Group 2: Stock Exchange Listing - Reed's common stock has been approved for listing on the NYSE American, with trading commencing on December 5, 2025, leading to the termination of trading on the OTC Markets' OTCQX Best Market [3]. Group 3: Company Background - Reed's, Inc. is a leader in the craft beverage industry, established in 1989, and offers high-quality, premium beverages under the Reed's®, Virgil's®, and Flying Cauldron® brand names, with products available in over 32,000 stores nationwide [5].

Core Viewpoint - Protara Therapeutics, Inc. has announced a public offering of 13,043,479 shares of common stock priced at $5.75 per share, aiming to raise approximately $75 million for clinical development and other corporate purposes [1]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,956,521 shares at the public offering price [1]. - The offering is expected to close on December 8, 2025, pending customary closing conditions [1]. - Protara intends to use the net proceeds for the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1]. Group 2: Underwriters and Management - J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering [2]. - LifeSci Capital is serving as the lead manager, while H.C. Wainwright & Co. is acting as a manager of the offering [2]. Group 3: Regulatory Information - The shares will be issued under an effective shelf registration statement on Form S-3, declared effective on November 14, 2023, by the U.S. Securities and Exchange Commission [3]. - A final prospectus supplement will be filed with the SEC and will be available on their website [3].

Core Viewpoint - Miata Metals Corp. is conducting a public offering of common shares at a price of $0.48 per share, aiming to raise up to $10,000,080, with the potential for total gross proceeds of $11,500,080 if the over-allotment option is fully exercised [1][2]. Group 1: Offering Details - The offering is being managed by a syndicate of agents led by Cormark Securities Inc., which has been granted an over-allotment option to sell an additional 3,125,000 common shares [2]. - The closing of the offering is anticipated to occur around December 8, 2025, pending regulatory approval [4]. Group 2: Company Information - Miata Metals Corp. is a Canadian mineral exploration company listed on the Canadian Securities Exchange, OTCQB, and Frankfurt Exchanges, focusing on the acquisition, exploration, and development of mineral properties [6]. - The company holds a 70% interest in the Sela Creek Gold Project, covering approximately 215 km², and a 70% beneficial interest in the Nassau Gold Project in Suriname, both of which are located in the greenstone belt of Suriname [6].

Core Viewpoint - Protara Therapeutics, Inc. has announced a public offering of $75 million in common stock or pre-funded warrants to fund clinical development and other corporate purposes [1]. Group 1: Offering Details - The offering consists of $75 million in shares of common stock or pre-funded warrants, with the possibility of underwriters purchasing additional shares within 30 days [1]. - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - Protara intends to use the net proceeds from the offering to fund the clinical development of TARA-002 and other clinical programs [1]. - Additional uses for the proceeds may include working capital and general corporate purposes [1]. Group 3: Regulatory Information - The shares and warrants will be issued under a shelf registration statement declared effective by the SEC on November 14, 2023 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3].

https://t.co/Yber9So4ea is set to begin trading Wednesday morning in Singapore’s biggest initial public offering since 2017 excluding real estate investment trusts https://t.co/dPLXe0IOSB ...

Core Viewpoint - Pasithea Therapeutics Corp. has successfully closed a public offering of 80 million shares at $0.75 per share, raising approximately $60 million in gross proceeds, which will be used for general corporate purposes and to extend its cash runway through at least the first half of 2028 [1][3][8]. Group 1: Offering Details - The public offering consisted of 80,000,000 shares of common stock or pre-funded warrants at an offering price of $0.75 per share [1]. - The offering was led by healthcare-focused investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management [1][8]. - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for general corporate purposes, including ongoing research, pre-clinical studies, clinical trials, and the development of new technologies [3]. - The company plans to invest in or acquire synergistic companies and engage in licensing activities related to its current and future product candidates [3]. Group 3: Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1-associated plexiform neurofibromas [6]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients and a Phase 1/1b clinical trial in adult patients with NF1-associated plexiform neurofibromas [6].

Company News - First Digital Group (FDUSD issuer) plans to go public via merger with CSLM Digital Asset Acquisition Corp III [1]